Precision Optics Corporation (NasdaqCM:POCI) Q1 2026 Earnings Call November 13, 2025 05:00 PM ET Speaker1Afternoon, and welcome to the Precision Optics Q1 2026 earnings event. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your touchscreen telephones. To withdraw your ques ...

Conference Call Scheduled for today, November 13, 2025, at 5:00pm ETGARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025. Q1 2026 Financial Highlights (3 Months Ended September 30, 2025): Revenue was $6.7 million, a q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-10647 PRECISION OPTICS CORPORATION, INC. (Exact name of registrant as specified in its charter) Massachusetts 04-279 ...

GARDNER, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to design and build a next generation borescope system to be used to inspect the inside of jet engines from a large aerospace and defense company. The system involves the development of a high-end, small-diameter borescope designed in ...

GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to build sub-assemblies that will support an advanced augmented reality (AR) system for US Air Force fighter pilot training, powered by POC’s next-generation optical sub-assembly design and manufacturing technologies. The program aims ...

GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company’s first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the m ...

Group 1 - The article does not provide any specific content related to a company or industry, as it appears to be a technical issue regarding browser settings and ad-blockers [1]

Summary of Precision Optics Corporation Conference Call Company Overview - **Company Name**: Precision Optics Corporation - **Ticker Symbol**: POCI - **Industry**: Medical Devices and Defense Aerospace - **Core Technology**: Focus on optics, particularly in micro optics, 3D imaging, and digital imaging [3][10][14] Key Financial Highlights - **Fiscal Year 2025 Revenue**: Reported total revenue of $6,200,000, with guidance for fiscal year 2026 set at $25,000,000, indicating a growth of over 30% [9][42] - **Backlog**: Record backlog of nearly $18,000,000, providing better visibility into future revenue [41] - **Gross Margin**: Expected recovery to 30% from a low of 18% due to startup challenges and increased production demands [42][43] Business Model and Strategy - **Product Development and Manufacturing**: The company engages in product development on a time and materials basis while retaining ownership of intellectual property (IP) [5][6] - **Focus on Single-Use Endoscopes**: The introduction of single-use endoscopes is a key driver for revenue growth, addressing safety concerns and operational efficiency in hospitals [19][20] - **Expansion into Defense Aerospace**: The company is beginning to explore opportunities in the defense aerospace market, leveraging its micro optics technology [21][37] Core Technologies 1. **Micro Optics**: Development of extremely small optics, including lenses and prisms, with applications in medical devices [11][12] 2. **3D Imaging**: Capabilities expanded to include ultra-high precision imaging for robotic surgical systems and augmented reality applications [12][13] 3. **Digital Imaging**: Utilization of CMOS sensors for medical endoscopes, improving image quality and reducing costs [14][18] Market Applications - **Medical Device Market**: Focus on minimally invasive surgeries, with products in various disciplines such as urology, cardiology, and otoscopy [15][16][17] - **Defense Aerospace Market**: Targeting applications that require smaller size, weight, and power (SWAP) for optical imaging and communication devices [22] Recent Developments - **Facility Updates**: Recent moves to consolidate and update facilities to support growth, including relocating headquarters closer to engineering talent [39][40] - **Unity Platform**: Introduction of a modular design approach to accelerate time to market and reduce development costs [25][26] Future Outlook - **Growth Expectations**: Anticipation of significant growth in manufacturing revenue and recovery in product development revenue as new programs enter production [10][36] - **Investment in R&D**: Continued investment in research and development to maintain competitive advantage and explore new market opportunities [37][41] Conclusion - Precision Optics Corporation is positioned for substantial growth driven by its innovative technologies in the medical device and defense aerospace sectors, with a strong focus on single-use products and a robust backlog supporting future revenue increases [41][42][45]

Core Viewpoint - Precision Optics Corporation will participate in the Lytham Partners Fall 2025 Investor Conference, hosting a webcast presentation and one-on-one meetings with investors on September 30, 2025 [1][2][3]. Company Overview - Precision Optics Corporation, founded in 1982, is a vertically integrated optics company focused on advanced optical instruments for the medical and defense/aerospace industries [4]. - The company leverages proprietary micro-optics, 3D imaging, and digital imaging technologies to provide services from product concept to mass manufacture [4]. - Precision Optics supports next-generation medical device companies by providing enhanced imaging systems for minimally invasive surgery and 3D endoscopy systems [4]. - The company has a long history of supplying optical products, including complex endocouplers and specialized endoscopes, to top-tier medical device companies [4]. - In the defense/aerospace sector, Precision Optics applies its technical proficiency in micro-optics to meet high-quality standards while optimizing size, weight, and power [4].

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue of $6.2 million for Q4 of fiscal 2025, compared to $4.2 million in the previous quarter and $4.7 million in Q4 of fiscal 2024, leading to an annualized run rate of approximately $25 million [5][23] - Gross margins for Q4 were 13%, up from 10% in the prior quarter but down from 22% in the same quarter last year, with annual gross margins at 18% compared to 30% in the prior year [25][28] - The company expects fiscal 2026 revenue to reach approximately $25 million, an increase of over 30% from $19 million in fiscal 2025, with gross margins projected to improve to around 30% [21][25] Business Line Data and Key Metrics Changes - Production revenue for Q4 was $5.1 million, up from $3.3 million in the previous quarter and $2.8 million in the year-ago quarter, while engineering revenue was $1.1 million, down from $1.9 million year-over-year [23] - The systems manufacturing business is expected to grow at least 75% in fiscal 2026, driven by the expansion of two major production programs [14][21] - Revenue from the micro-optics lab is projected to decline from $2.1 million in fiscal 2025 to $1.3 million in fiscal 2026 due to timing of a large defense customer reorder [24] Market Data and Key Metrics Changes - The company has seen a significant increase in production demand from its aerospace and surgical robotics customers, with a backlog for the aerospace program reaching nearly $9 million [10][24] - The transition of two major programs from development to production has provided increased visibility and confidence in future revenue growth [6][7] Company Strategy and Development Direction - The company is focusing on expanding its production capabilities and has invested in new facilities to support growth, including a move to a new headquarters in Littleton, Massachusetts [7][8] - The management is optimistic about the future, citing a strong backlog and the potential for substantial growth as production programs expand [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges with gross margins in Q3 and Q4 of fiscal 2025 but expressed confidence in recovery and improvement in fiscal 2026 [15][21] - The company is taking steps to address production yield issues and has renegotiated pricing with customers to improve profitability [12][13] Other Important Information - The company has hired new manufacturing and quality engineers to strengthen its operations team and improve manufacturing efficiency [19][20] - The company expects to recover positive adjusted EBITDA in the range of half a million dollars for fiscal 2026 [21] Q&A Session Summary Question: Guidance on revenue for 2026 - Management acknowledged being conservative in their guidance, noting a decline in revenue from the micro-optics lab but expecting higher margin production revenue to replace lower margin tooling and fixturing revenue [35][37] Question: Medical program pricing adjustments - Management explained that they have negotiated higher costs with their medical program customer to cover initial production difficulties, with a plan to ramp down prices as issues are resolved [40][41] Question: Tariff reimbursements - Management confirmed they are in verbal agreements for tariff reimbursements and are finalizing documentation [42][43] Question: Engineering resources and project pipeline - Management indicated that engineering resources will be progressively filled throughout 2026, with multiple programs lined up for production [49][50] Question: Challenges with the second single-use program - Management reported that the second single-use program is progressing well, learning from challenges faced in the cystoscope program, and expects a smoother ramp-up [62]